Bioo Scientific Corp. Receives NIH Grant for the Development of Novel Anti-Viral Therapeutics
News May 05, 2009
When a virus uncoats its genome after it infects a cell, the cell theoretically has a golden opportunity to attack the unprotected genome before it starts the process of making viral-specific products that cause problems in the cell.
Researchers at Colorado State University have recently discovered a mechanism by which several viruses specifically suppress aspects of the cell in order to stabilize their nucleic acids to promote an efficient infection. This finding has revealed a prospective 'Achilles' heel' for viruses that has significant therapeutic potential.
In a partnership with Colorado State and the Rocky Mountain Regional Center of Excellence in Biodefense and Emerging Diseases, Bioo Scientific recently received a $1.25 million, 5 year grant award to develop novel methodologies and compounds that will specifically overcome this viral suppression mechanism and allow cells to effectively attack viral nucleic acids.
“We are pleased to be able to contribute our expertise in drug discovery and development to this project” said Dr. Lance Ford, Bioo’s VP for Research and Development.
“We are also very much looking forward to working with the cadre of biodefense-oriented microbiologists in the Rocky Mountain region. One aspect of the project that we find particularly exciting is that the treatments we will be developing could then be used to treat infections with multiple viruses of biodefense significance. Theoretically, the therapeutics could even be effective against rapidly evolving viruses like influenza,” Dr. Ford continued.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018